Annovis Bio (ANVS)

• Market cap: $91.7M
• 1 day: -1.14%
• 5 days: -11.05%
• 1 month: -23.28%
• 3 months: 67.15%
• 6 months: 59.45%
• Year to date: -32.29%
• 1 year: -31.89%
• 5 years: -52.86%
• 10 years: -63.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Employees: 6